IL129168A - Sulfonamides, process for their preparation and process for their reduction - Google Patents

Sulfonamides, process for their preparation and process for their reduction

Info

Publication number
IL129168A
IL129168A IL12916899A IL12916899A IL129168A IL 129168 A IL129168 A IL 129168A IL 12916899 A IL12916899 A IL 12916899A IL 12916899 A IL12916899 A IL 12916899A IL 129168 A IL129168 A IL 129168A
Authority
IL
Israel
Prior art keywords
sulfonamides
reduction
preparation
Prior art date
Application number
IL12916899A
Other languages
English (en)
Other versions
IL129168A0 (en
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of IL129168A0 publication Critical patent/IL129168A0/xx
Publication of IL129168A publication Critical patent/IL129168A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/30—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/36—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids
    • C07C303/40—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of amides of sulfonic acids by reactions not involving the formation of sulfonamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
IL12916899A 1998-04-10 1999-03-25 Sulfonamides, process for their preparation and process for their reduction IL129168A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8131098P 1998-04-10 1998-04-10

Publications (2)

Publication Number Publication Date
IL129168A0 IL129168A0 (en) 2000-02-17
IL129168A true IL129168A (en) 2003-07-06

Family

ID=22163376

Family Applications (2)

Application Number Title Priority Date Filing Date
IL12916899A IL129168A (en) 1998-04-10 1999-03-25 Sulfonamides, process for their preparation and process for their reduction
IL13877899A IL138778A0 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL13877899A IL138778A0 (en) 1998-04-10 1999-04-09 Process for alkylating hindered sulfonamides useful in the production of matrix metalloproteinase inhibitors

Country Status (47)

Country Link
US (2) US6229025B1 (de)
EP (2) EP0949245B1 (de)
JP (2) JP3479511B2 (de)
KR (2) KR100357660B1 (de)
CN (3) CN1234396A (de)
AP (1) AP1095A (de)
AR (1) AR017731A1 (de)
AT (2) ATE206392T1 (de)
AU (2) AU755004B2 (de)
BG (1) BG63665B1 (de)
BR (2) BR9910110A (de)
CA (2) CA2268684C (de)
CO (1) CO4810299A1 (de)
DE (2) DE69900321T2 (de)
DK (1) DK0949245T3 (de)
DZ (1) DZ2754A1 (de)
EA (1) EA002277B1 (de)
EG (1) EG21985A (de)
ES (2) ES2163316T3 (de)
GT (1) GT199900047A (de)
HN (1) HN1999000043A (de)
HR (1) HRP990106B1 (de)
HU (2) HUP9901043A1 (de)
ID (2) ID23244A (de)
IL (2) IL129168A (de)
IN (1) IN192485B (de)
IS (1) IS5018A (de)
MA (1) MA24833A1 (de)
NO (1) NO991675L (de)
NZ (1) NZ335105A (de)
OA (1) OA11030A (de)
PA (1) PA8469601A1 (de)
PE (1) PE20000417A1 (de)
PL (2) PL343530A1 (de)
PT (1) PT949245E (de)
RU (1) RU2197479C2 (de)
SA (1) SA99200089A (de)
SG (1) SG75167A1 (de)
SK (1) SK45399A3 (de)
TN (1) TNSN99054A1 (de)
TR (2) TR199900756A2 (de)
TW (1) TW520354B (de)
UA (1) UA57039C2 (de)
UY (1) UY25469A1 (de)
WO (1) WO1999052862A1 (de)
YU (1) YU18399A (de)
ZA (2) ZA992627B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458822B2 (en) 2000-03-13 2002-10-01 Pfizer Inc. 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
EP1134207A1 (de) * 2000-03-15 2001-09-19 Pfizer Products Inc. Verfahren zur Herstellung von Resorcinolderivaten
EP1208092B1 (de) * 2000-04-07 2006-06-21 Samsung Electronics Co., Ltd. Sulfonamide als matrix-metalloproteinase inhibitoren
US20020073441A1 (en) 2000-12-13 2002-06-13 Ross Brian D. Compositions and methods for detecting proteolytic activity
US6844373B2 (en) * 2002-05-28 2005-01-18 Alcatel Composition comprising fluorinated, radiation-curable dyes for surface energy control
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
ITFI20040174A1 (it) * 2004-08-03 2004-11-03 Protera S R L Derivati arilsolfonammidici dell'acido idrossammico ad azione inibitoria di metalloproteinasi
ITBO20050005U1 (it) * 2005-01-31 2006-08-01 Ali Spa Distributore di bevande ghiacciate e simili

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU523636A3 (ru) * 1973-06-18 1976-07-30 Стауффер Кемикал Компани (Фирма) Способ получени сульфоксидных или сульфоновых производных тиокарбаматов
ZA794723B (en) 1978-09-11 1980-08-27 Univ Miami Anti-hypertensive agents
GB9000725D0 (en) 1990-01-12 1990-03-14 Pfizer Ltd Therapeutic agents
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
US5863949A (en) * 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PL331895A1 (en) * 1996-08-23 1999-08-16 Pfizer Arylosulphonylamino derivatives of hydroxamic acid
AU721748B2 (en) 1997-02-03 2000-07-13 Pfizer Products Inc. Arylsulfonylamino hydroxamic acid derivatives
ID23668A (id) 1997-08-08 2000-05-11 Pfizer Prod Inc Turunan asam ariloksiarilsulfonilamino hidroksamat
ES2176913T3 (es) 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico

Also Published As

Publication number Publication date
UA57039C2 (uk) 2003-06-16
ATE206392T1 (de) 2001-10-15
ZA992627B (en) 2000-10-09
UY25469A1 (es) 1999-11-17
ATE284864T1 (de) 2005-01-15
BR9902219A (pt) 2000-04-11
HRP990106B1 (en) 2003-08-31
EP1068180B1 (de) 2004-12-15
TNSN99054A1 (fr) 2005-11-10
AU3552799A (en) 1999-11-01
CO4810299A1 (es) 1999-06-30
AU755004B2 (en) 2002-11-28
JP2002511447A (ja) 2002-04-16
IL129168A0 (en) 2000-02-17
CA2327498A1 (en) 1999-10-21
US6114568A (en) 2000-09-05
BG103320A (en) 2001-08-31
AU760213B2 (en) 2003-05-08
CN1296474A (zh) 2001-05-23
YU18399A (sh) 2002-11-15
NZ335105A (en) 2000-03-27
PT949245E (pt) 2002-02-28
DE69922638T2 (de) 2005-05-19
US6229025B1 (en) 2001-05-08
ID27208A (id) 2001-03-08
AU2369199A (en) 1999-10-21
EP1068180A1 (de) 2001-01-17
IS5018A (is) 1999-10-11
IL138778A0 (en) 2001-10-31
KR20010042567A (ko) 2001-05-25
HU9901043D0 (en) 1999-06-28
KR100377718B1 (ko) 2003-03-26
RU2197479C2 (ru) 2003-01-27
NO991675L (no) 1999-10-11
ID23244A (id) 2000-03-30
CN1288885A (zh) 2001-03-28
ZA200005370B (en) 2002-01-03
TR200002950T2 (tr) 2000-12-21
KR100357660B1 (ko) 2002-10-25
PL332451A1 (en) 1999-10-11
PA8469601A1 (es) 2000-09-29
DE69922638D1 (de) 2005-01-20
CA2327498C (en) 2006-01-31
MA24833A1 (fr) 1999-12-31
WO1999052862A1 (en) 1999-10-21
DZ2754A1 (fr) 2003-09-15
TR199900756A2 (xx) 1999-11-22
SK45399A3 (en) 2000-08-14
SA99200089A (ar) 2005-12-03
EA199900277A2 (ru) 1999-10-28
HRP990106A2 (en) 1999-12-31
SG75167A1 (en) 2000-09-19
CA2268684C (en) 2004-07-13
BG63665B1 (bg) 2002-08-30
CA2268684A1 (en) 1999-10-10
HUP0101465A3 (en) 2002-11-28
DE69900321T2 (de) 2002-07-11
DE69900321D1 (de) 2001-11-08
EP0949245A1 (de) 1999-10-13
BR9910110A (pt) 2001-10-09
HUP0101465A2 (hu) 2002-03-28
TW520354B (en) 2003-02-11
IN192485B (de) 2004-04-24
AR017731A1 (es) 2001-09-12
PL343530A1 (en) 2001-08-27
AP9901506A0 (en) 1999-06-30
OA11030A (en) 2002-02-07
NO991675D0 (no) 1999-04-09
EA002277B1 (ru) 2002-02-28
JP3540959B2 (ja) 2004-07-07
PE20000417A1 (es) 2000-05-24
KR19990082986A (ko) 1999-11-25
CN1234396A (zh) 1999-11-10
HUP9901043A1 (hu) 2000-08-28
EP0949245B1 (de) 2001-10-04
HN1999000043A (es) 1999-11-03
ES2234253T3 (es) 2005-06-16
DK0949245T3 (da) 2002-01-28
AP1095A (en) 2002-08-26
JP2000026400A (ja) 2000-01-25
EA199900277A3 (ru) 2000-04-24
GT199900047A (es) 2000-09-15
ES2163316T3 (es) 2002-01-16
JP3479511B2 (ja) 2003-12-15
EG21985A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
HUP9900163A3 (en) Process for the preparation of sterol-and stanol-esters, and use thereof
HUP0102833A3 (en) Cyclosporins, process for preparation thereof and their use
DE69941083D1 (en) 12,13-cyclopropan-epothilonderivate
HUP9904631A3 (en) Fine-grained caoutchouc-powders, procedure for making them and the use thereof
GB0106312D0 (en) Process
PL351250A1 (en) Antipicornaviral compounds, their preparation and use
AU7773001A (en) Acylacetonitriles, process for preparation thereof and miticides containing the same
GB2345286B (en) Photoresist copolymer, process for preparing the same and photoresist composition comprising the same
HUP0104819A3 (en) Chroman derivatives, their use intermediate and process for their preparation
HUP0003452A3 (en) Process for the preparation of 1-aryl-3-cyclopropyl-1,3-propanediones
HUP0101235A3 (en) Hyperhydrated citicoline, process for preparing it and use
SI0863139T1 (en) Benzoxazindione derivatives, process for their preparation and their use
IL140417A0 (en) NOVEL COMPOUNDS DERIVED FROM β-D-XYLOSE, PREPARATION METHOD AND THERAPEUTIC USE
AU3820699A (en) Catalyst and process for its preparation
DE59901937D1 (en) Transportabler grossbehälter, insbesondere flugtransportfähiger container
HUP0102988A3 (en) Peroxides, their preparation process and use
HUP0103569A3 (en) New medicament and process for its preparation
HUP9901529A3 (en) Propynyl compounds, process for their preparation and their use
HUP0102297A3 (en) Process for preparation of 4,5-epoxymorphinan-6-oxi-glucuronides
LT98110A (en) Polytetra-ammonium salt, method for preparation and use thereof
ZA99220B (en) Triazepinones, process for their preparation and their therapeutic application.
HU9801027D0 (en) Laser-inks, process for making and use thereof
GB9811172D0 (en) Virus production
GB2335866B (en) Process
SI1073672T1 (en) Antipicornaviral compounds, their preparation and use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees